Category: Research

Summaries and explanations of new research aimed at identifying the causes of and cures for Charcot Marie Tooth disease (CMT).

  • Diagnostic Pathways for Idiopathic Neuropathy

    Diagnostic Pathways for Idiopathic Neuropathy

    “You have a serious illness of an undisclosed nature.”

  • CIDP and CMT

    CIDP and CMT

    I’ve been interested in the diseases and disorders that can be mis-diagnosed as CMT (or vice versa) for a while. One that has come up a lot is Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP). CIDP can look like CMT cases where demyelination is prominent, usually Type 1/1A. In one international study of more than 1,100 people…

  • Physical and Emotional Pain Need Equal Attention in CMT and Polyneuropathy Communities

    Physical and Emotional Pain Need Equal Attention in CMT and Polyneuropathy Communities

    Alongside research for treatments and cures, the CMT community needs to take a hard look at some elephants in the room — the most common and most remnediable pains and struggles impacting our quality of daily life.

  • Differential Diagnosis with Dr. ChatGPT-4 in the House

    Differential Diagnosis with Dr. ChatGPT-4 in the House

    In a matter of seconds, ChatGPT reviewed and confirmed the findings of three neurologists and a genetic counselor that took me six years to gather. It also suggested a new diagnostic path that was only vaguely hinted at by the human diagnosticians.

  • The “First Treatable CMT Disease” is Neither CMT Nor a Disease

    The “First Treatable CMT Disease” is Neither CMT Nor a Disease

    CMT-related research may truly do away with CMT disease first by eliminating or updating how naming and classification works in neurological pathology.

  • New Gene (PSAT1) Linked to Treatable CMT-like Outcomes

    New Gene (PSAT1) Linked to Treatable CMT-like Outcomes

    Two new and treatable cases of peripheral neuropathy reported in children raise more questions about the definition and diagnosis of CMT types.

  • Physical Assessments for CMT

    Physical Assessments for CMT

    There are several validated assessment instruments for CMT to take stock of its current and later states of progression.

  • CMT, Depression, and Anxiety

    CMT, Depression, and Anxiety

    It’s not surprising to learn from another (and more detailed) study (summarized here) than I’ve seen before that people with CMT are very often dealing with depression and/or anxiety, especially with more severe versions of the disease, and many go “untreated.” “Untreated” in this case means “unmedicated,” and there is a lot more that can…

  • Conference Videos Worth Watching

    The 2022 CMT Patient and Research Summit has all its session recordings online now. These are mostly research-oriented, but not all. It’s good to see a few sessions on therapy and things you can do for yourself, in addition to the research focused on specific CMT subtypes. Of note: CMT is a Multi-System Disease by…

  • The “first treatable” form of CMT?

    The “first treatable” form of CMT?

    I wrote this brief article on the way the SORD gene works (or fails to work) for the Hereditary Neuropathy Foundation. SORD mutations cause “the most common autosomal recessive form of CMT2 (CMT2A1), autosomal recessive intermediate CMT (CMTRIA), and the overlapping category of distal hereditary motor neuropathy (dHMN).”

  • All types of CMT are “Axonal”

    All types of CMT are “Axonal”

    CMT1 types have commonly been referred to as “demyelinating” and CMT2 as “axonal,” which gives the impression the nature of the nerve damage between the two is fundamentally different.

  • The Problem With Writing About CMT

    The Problem With Writing About CMT

    I’ve been increasingly irritated lately by US-based CMT-related non-profit organizations that seem to compete with each other for donations — supposedly they drive research for “treatments and cures.” How well they actually do this relative to the padding of their own budgets is a good question I might take up down the line, but you…

  • Maybe it will work on CMT..?

    Maybe it will work on CMT..?

    It seems the new hope for VM202 as a CMT1a treatment is perhaps Hellxmith’s latest attempt to find a market for an experimental product that has not panned out as hoped.

  • CMT Blogs of Note

    CMT Blogs of Note

    Two blogs about CMT I found recently: the MFN2 Project and Help Chronic Pain in Alberta.

  • A new discovery of a genetic cause (and likely cure) for a previously unknown subtype of CMT2

    A new discovery of a genetic cause (and likely cure) for a previously unknown subtype of CMT2

    Published in Nature Genetics last month, the INC group’s findings are a big deal, and there is a really cool story from the University of Miami’s Miller School of Medicine about how the research team came together.

  • New Study of Genetic Causes of CMT Needs Participants

    New Study of Genetic Causes of CMT Needs Participants

    The Rare Diseases Network is looking for participants in a new study looking for unknown causes of the most common types of CMT.

  • CMT and COVID-19

    CMT and COVID-19

    The Inherited Neuropathy Consortium (INC) is asking for CMTers with a COVID diagnosis to take an anonymous questionnaire.

  • CMT’s Impact on Quality of Life Can Be Slight

    CMT’s Impact on Quality of Life Can Be Slight

    Even though the measurable electrophysiological impact of CMT1A is high, the subjective level of experienced disability is pretty low, given the ways you can learn to compensate.

  • Genetic Cause of CMT2 Discovered?

    Genetic Cause of CMT2 Discovered?

    A recent study published in the Journal of Clinical Investigation looked at two unrelated families with CMT2 and identified “autosomal dominant mutations of the canonical Notch ligand Jagged1 (or JAG1)” in them — a likely cause for their CMT that was also backed up by experiments in mice. The CMT News site covers this in…

  • ACE-083 Trials Show No Benefit

    ACE-083 Trials Show No Benefit

    Acceleron Pharma Inc’s ACE-083 drug trials “did not achieve statistically significant improvements in functional endpoints relative to placebo” with CMT patients, so it will no longer be developed.

  • CMT and Respiratory Dysfunction

    CMT and Respiratory Dysfunction

    Science is starting to confirm very wide ranging effects to the nerve damage CMT does, often slowly and over time so it may not be very noticeable for many years.

  • New Genetic Diagnostics for CMT

    New Genetic Diagnostics for CMT

    Here’s an informative article from the Hereditary Neuropathy Foundation (HNF) about current best practices in genetic diagnosis of CMT. A lot of examples are given of people with less common subtypes who waited a long time to get properly diagnosed — sometimes after many years of wrong diagnoses or none at all. Today the best…

  • Second Phase 3 Clinical Trial for CMT1A “Pleodrug”

    Second Phase 3 Clinical Trial for CMT1A “Pleodrug”

    After the setback of having to do a second Phase 3 clinical trial, Pharnext’s ongoing drug trials for PXT3003 show positive results in people with CMT1A.

  • Should I play the didgeridoo (or harmonica) to fight sleep apnea‽

    Should I play the didgeridoo (or harmonica) to fight sleep apnea‽

    Some recent studies on obstructive sleep apnea got attention for concluding something fairly obvious — losing weight and reducing fat in the tongue might be the best treatment for OSA.

  • Respiratory Problems and CMT

    Respiratory Problems and CMT

    Earlier in life, relatively healthy people with CMT can overlook signs of compromised respiratory function which will start to cause more and more problems for them later.

  • Sleep Apnea and CMT

    Sleep Apnea and CMT

    Studies show CMT tends to come with Disturbed Sleep, Depression, and Reduced Quality of Life. 😞 This post summarizes the scientific research I’ve absorbed on the subject of CMT and sleep apnea. It’s definitely accurate relative to my own experience in the past year or so.

  • The State of Research for Cures (2019)

    The State of Research for Cures (2019)

    The US-based CMTA (Charcot Marie Tooth Association) has a 12-year-old program called the Strategy to Accelerate Research (STAR) that is actively pursuing the causes and possible cures for CMT. STAR will cover nearly all CMT Type 1s and 2s, including types with as yet unidentified genetic causes.